EFFECT OF FILGOTINIB ON PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE PHASE 3 FINCH 1, 2 AND 3 STUDIES

Taylor, P.C ; Kavanaugh, A ; Nash, P ; Pope, J ; Pongratz, G ; Fautrel, B ; Alten, R ; Hasegawa, K ; Rao, S ; De Vries, D ; Stiers, P.J ; Watson, C ; Westhovens, R

BMJ PUBLISHING GROUP

Texto completo disponível

A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn's disease

Bettenworth, D ; Baker, M.E ; Bemelmann, W ; Bruining, D ; D'Haens, G ; D'Hoore, A ; Dignass, A ; Dotan, I ; Feagan, B.G ; Feakins, R ; Fleshner, P ; Fletcher, J.G ; Gordon, I ; Ha, C ; Gaylyn, H ; Jairath, V ; Lu, C ; Lyu, R ; Ng, S.C ; Panes, J ; Rogler, G ; Mao, R ; Rimola, J ; Sandborn, W.J ; Siegmund, B ; Silverberg, M.S ; Taylor, S ; Verstockt, B ; Rieder, F

OXFORD UNIV PRESS

Texto completo disponível

IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY

Behrens, F ; Taylor, P.C ; Wetzel, D ; Brun, N.C ; Brandt-Juergens, J ; Drescher, E ; Dokoupilova, E ; Rowinska-Osuch, A ; Martin, N. Abdel-Kader ; de Vlam, K

BMJ PUBLISHING GROUP

Texto completo disponível

Theoretical modelling in bioengineering: 12th Haughton Lecture of the Royal Academy of Medicine in Ireland

Taylor, D

Texto completo disponível

Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD

Aftimos, P.G ; Cortes, J ; Bidard, F.C ; Kaklamani, V ; Bardia, A ; Neven, P ; Streich, G ; Montero, A ; Forget, F ; Reynier, M.A. Mouret ; Sohn, J ; Taylor, D ; Harnden, K ; Khong, H ; Kocsis, J ; Dalenc, F ; Dillon, P ; Tonini, G ; Grzegorzewski, K.J ; Lu, J

ELSEVIER

Texto completo disponível